Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Naos Institute Of Life Science has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current applications are being reviewed in different technical departments.
STEVENS, MARK V is the busiest examiner for the portfolio, responsible for 1 pending office action. With 2 distinct examiners and 2 distinct art units, the prosecution workload is split across multiple specialized groups.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| ALAM, AYAAN A | 1 | 38.4% | +35.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257526 | GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF | STEVENS, MARK V | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257440 | USE OF BACTERIORUBERINS AND GLYCOSYL DERIVATIVES THEREOF TO PREVENT AND TREAT DISEASES INVOLVING DYSREGULATED PROTEIN AGGREGATION, SUCH AS NEURODEGENERATIVE DISEASES | ALAM, AYAAN A | 4d overdue |
| 18257526 | GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF | STEVENS, MARK V | 5d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257526 | GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF | STEVENS, MARK V | 1613 | §103§112Other | Non-Final OA | 5d | Pending | Jun 14, 2023 |
| 18257440 | USE OF BACTERIORUBERINS AND GLYCOSYL DERIVATIVES THEREOF TO PREVENT AND TREAT DISEASES INVOLVING DYSREGULATED PROTEIN AGGREGATION, SUCH AS NEURODEGENERATIVE DISEASES | ALAM, AYAAN A | 1611 | §103§112DP | Final Rejection | 4d overdue | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial